ERBB2 and breast cancer: In turn, we have expanded previous knowledge on acquired resistance to palbociclib by confirming CCNE1 overexpression/amplification and reduced expression/loss of RB1 as common events that occur at the time of acquired resistance in luminal BC cell lines, independent of HER2 status.